<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04383418</url>
  </required_header>
  <id_info>
    <org_study_id>HR0171401-301</org_study_id>
    <nct_id>NCT04383418</nct_id>
  </id_info>
  <brief_title>A Trial of Dexmedetomidine Hydrochloride Nasal Spray in Preoperative Sedation of Adults</brief_title>
  <official_title>Study on Efficacy and Safety of Dexmedetomidine Hydrochloride Nasal Spray for Preoperative Sedation in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate the efficacy, and safety of dexmedetomidine&#xD;
      hydrochloride nasal spray for preoperative sedation in adults. To explore the reasonable&#xD;
      dosage of dexmedetomidine hydrochloride nasal spray for preoperative sedation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 31, 2020</start_date>
  <completion_date type="Anticipated">September 10, 2021</completion_date>
  <primary_completion_date type="Actual">June 2, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Dexmedetomidine hydrochloride nasal spray compared with placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who meet the Ramsay sedation score of 3 at least once within 45 minutes</measure>
    <time_frame>0 minute to 45 minutes after administration</time_frame>
    <description>Evaluated with Ramsay sedation scale Score Response&#xD;
Anxious or restless or both&#xD;
Cooperative, orientated and tranquil&#xD;
Responding to commands&#xD;
Brisk response to stimulus&#xD;
Sluggish response to stimulus&#xD;
No response to stimulus</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total consumption of propofol during bispectral index reaches 60 for the first time</measure>
    <time_frame>The bispectral index reaches 60 for the first time during intraoperative</time_frame>
    <description>Total consumption of propofol during bispectral index reaches 60 for the first time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total consumption of propofol during general anesthesia</measure>
    <time_frame>From the beginning of anesthesia to the end of surgical operation up to 4 hours</time_frame>
    <description>Total consumption of propofol during general anesthesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total consumption of opioid analgesic during bispectral index reaches 60 for the first time</measure>
    <time_frame>The bispectral index reaches 60 for the first time during intraoperative</time_frame>
    <description>Total consumption of opioid analgesic during bispectral index reaches 60 for the first time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total consumption of opioid analgesic during general anesthesia</measure>
    <time_frame>From the beginning of anesthesia to the end of surgical operation up to 4 hours</time_frame>
    <description>Total consumption of opioid analgesic during general anesthesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The BIS value for the Ramsay sedation score of 3 for the first time after administration</measure>
    <time_frame>The Ramsay sedation score of 3 for the first time during intraoperative</time_frame>
    <description>The BIS value for the Ramsay sedation score of 3 for the first time after administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anesthesiologist satisfaction rating</measure>
    <time_frame>At the end of surgery when the patient recovers from anesthesia</time_frame>
    <description>The anesthesiologist satisfaction rating is a scale of 0 to 10, satisfaction defined as a scale of 10, dissatisfaction defined as a scale of 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects' satisfaction rating</measure>
    <time_frame>From the end of surgical operation up to 24 hours</time_frame>
    <description>The subjects' satisfaction rating is a scale of 0 to 10, satisfaction defined as a scale of 10, dissatisfaction defined as a scale of 0.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">201</enrollment>
  <condition>Preoperative Sedation</condition>
  <arm_group>
    <arm_group_label>High dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the low dose group, 36 subjects will receive a low dose of dexmedetomidine nasal spray.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the high dose group, 36 subjects will receive a high dose of dexmedetomidine nasal spray.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In the placebo groupï¼Œ36 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexmedetomidine nasal spray</intervention_name>
    <description>dexmedetomidine nasal spray</description>
    <arm_group_label>High dose group</arm_group_label>
    <arm_group_label>Low dose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexmedetomidine hydrochloride nasal spray blank preparation</intervention_name>
    <description>dexmedetomidine hydrochloride nasal spray blank preparation</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able and willing to provide a written informed consent&#xD;
&#xD;
          2. Subjects requiring elective general anesthesia surgery&#xD;
&#xD;
          3. Male or female&#xD;
&#xD;
          4. Meet the weight standard&#xD;
&#xD;
          5. Conform to the ASA Physical Status Classification&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Not suitable for nasal spray&#xD;
&#xD;
          2. Subjects who had received general anesthesia&#xD;
&#xD;
          3. Subjects with a history of myocardial infarction or unstable angina pectoris&#xD;
&#xD;
          4. Subjects with atrioventricular block or cardiac insufficiency&#xD;
&#xD;
          5. Subjects with a history of ischemic stroke or transient ischemic attack&#xD;
&#xD;
          6. Subjects with poor blood pressure control after medication&#xD;
&#xD;
          7. Subjects with abnormal clotting function&#xD;
&#xD;
          8. Subjects with a history of mental illness and a history of cognitive impairment&#xD;
             epilepsy&#xD;
&#xD;
          9. Subjects with a history or possibility of a difficult airway&#xD;
&#xD;
         10. Subject with a history of substance abuse and drug abuse&#xD;
&#xD;
         11. Adrenoceptor agonists or antagonists were used before randomization&#xD;
&#xD;
         12. Abnormal values in the laboratory&#xD;
&#xD;
         13. Thyroid dysfunction&#xD;
&#xD;
         14. Allergic to a drug ingredient or component&#xD;
&#xD;
         15. Pregnant or nursing women&#xD;
&#xD;
         16. No birth control during the specified period of time&#xD;
&#xD;
         17. Participated in clinical trials of other drugs (received experimental drugs)&#xD;
&#xD;
         18. The inestigators determined that other conditions were inappropriate for participation&#xD;
             in this clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Changhong Miao, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongshan Hospital, Fudan University, Shanghai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 6, 2020</study_first_submitted>
  <study_first_submitted_qc>May 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

